Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Multiple MDUFA Policies In Transition Phase Until Jan. 1

This article was originally published in The Gray Sheet

Executive Summary

For now, CDRH remains in a transition phase on its new refuse-to-accept policies for PMA and 510(k) submissions and its mandate for electronic copies of pre-market submissions, each of which have been addressed in recent guidance documents.


Related Content

Washington Roundup, November-December 2012
Post-Election Picture: Near-Term Next Steps To Come
ODE Reorganization Reduces Reviewer-To-Manager Ratio
FDA Outlines Mandated eCopy Submission Program In Draft Guidance
Industry Says FDA’s “Refuse To Accept” 510(k) Guidance Is Too Subjective
FDA Charges Ahead With MDUFA III Implementation, Despite Budget Uncertainties
FDA Subject To More Oversight Following User Fee Bill Passage





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts